Coya Therapeutics, Inc.
COYAHealthcare|Biotechnology|US
$2.99
+0.18 (+6.41%)
DCF Value
$4.73
Tangible Book / Share
$1.84
Cash / Share
$1.84
Clinical Trials (1)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT07161999 Study of COYA 302 for the Treatment of ALS | Amyotrophic Lateral Sclerosis (ALS) | P2P3 | Active | 120 | RCT, Double-blind | COYA 302, Placebo |